Mark Fitzgerald

Mark Fitzgerald serves as the Director of Chemistry at Superluminal Medicines Inc. since October 2024. Prior experience includes roles at Nested Therapeutics as Chemistry Consultant and Director of Chemistry, where Mark contributed significantly to allosteric inhibitor and protein-protein interaction disruption projects in oncology. At C4 Therapeutics, Mark held the position of Associate Director of Chemistry, managing external teams and participating in lead optimization projects. Previous positions at the Broad Institute involved leading chemistry efforts on cancer-targeted projects and antibacterials, while initial roles included research positions at Pamlico Pharmaceutical Inc., 3-Dimensional Pharmaceuticals, and Provid Research, focusing on various therapeutic areas. Mark holds a B.A. in Chemistry from Rutgers University and a PhD in Organic Chemistry from the University of Pennsylvania.